Potential side effects can include brain swelling and bleeding. My October 6th article, “New Alzheimer’s Drug Reported to Substantially Decrease Cognitive Impairment,” is particularly relevant to this current piece due to a discussion of the drug that had recently received FDA approval. Last week, lecanemab was FDA-approved, and yet the drug’s listed side effects have been making equivalent news. Alzheimer’s Advancement, 2023According to a January 9th report from ScienceAlert.com, “FDA Approves New Alzheimer's Drug Designed to Slow Cognitive Decline,” the promise of the drug aside the potential side effects are causing concern. As excerpted from the report: The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized in a congressional reportfor its green-lighting of another Alzheimer's drug, Aduhelm.

Source: CNN January 09, 2023 23:17 UTC